Oncoceutics (United States)

Recent papers from Oncoceutics (United States)

1. Population pharmacokinetics for the CTLA‐4 modulator gotistobart in patients with advanced solid tumorsThe Journal of Clinical Pharmacology · 2026
2. Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancerClinical Cancer Research · 2026
3. Genotype-Specific Electrophysiological Remodeling in PLN R14del Cardiomyopathy: Implications for Precision Antiarrhythmic TherapyCirculation Arrhythmia and Electrophysiology · 2026
4. Multicenter phase 2 study of hydroxychloroquine (HCQ) and chlorphenesin carbamate (CPC) in combination with mFOLFIRINOX in patients with advanced pancreatic adenocarcinoma (PDAC).Journal of Clinical Oncology · 2026
5. Overall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumab.Journal of Clinical Oncology · 2026
6. Transcriptome-based Deep Learning Model for Predicting Gemcitabine and Cisplatin Chemotherapy Response in Urothelial Carcinoma: Development and External Validation.2026
7. Cancer care continuity under 2026 regional gulf conflict: experiences and a resilience framework from the Gulf StatesFrontiers in Oncology · 2026
8. Abstract CT273: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancersCancer Research · 2026
9. Abstract CT154: Clinical activity and safety of novel BRAF inhibitor plixorafenib (FORE8394) in BRAF V600-mutated advanced colorectal cancers (CRC)Cancer Research · 2026
10. Abstract 3106: OC201 and OC202e, an AI-driven drug combination, enhance the susceptibility of pancreatic cancer to FOLFIRINOX by modulating HIF-1αCancer Research · 2026
11. Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trialNature Medicine · 2026
12. Recommendations for the treatment of endometrial cancer in settings with limited resources: report from the International Gynecological Cancer Society consensus meetingFrontiers in Oncology · 2026
13. Transcriptomic deep learning approach for predicting chemotherapy response to cisplatin and gemcitabine in urothelial carcinoma.Journal of Clinical Oncology · 2026
14. Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology · 2026
15. Specific depletion of TIGIT high CD226 ⁻ clonally expanded intratumoral Tregs defines safe and effective TIGIT targetingJournal for ImmunoTherapy of Cancer · 2026
16. Trends in Neoadjuvant Pembrolizumab Use in Triple-Negative Breast CancerAmerican Journal of Clinical Oncology · 2026
17. Antibiotics and Surgical Site Infection in Expander-Based Breast Reconstruction Trial (ASSERT)Annals of Surgical Oncology · 2025
18. OncoMet: a deep learning framework for the prediction of oncogenic signaling pathways and metastasis in esophageal cancer patients using histopathology images from primary tumorsJournal of Translational Medicine · 2025
19. CD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under ART.2025
20. pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodiesProceedings of the National Academy of Sciences · 2025